CINXE.COM

<!DOCTYPE html> <html class="no-js" lang="en" prefix="og: https://ogp.me/ns#"> <head> <script src="https://sp-library.prod.sp.aws.clarivate.net/oti/latest/index.umd.js"></script> <link href="https://www.bioworld.com/articles/topic/214-deals-and-m-a" rel="canonical"> <meta charset="utf-8"> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="kywTfpB+J3C8RrEsWHVg6JEVntbiRWFPkth/y27yGUbFOSeNQRqRCCvNqen28ljeBDUij3eiFYNr+OLKUqUyBQ==" /> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta name="timestamp" value="2025-02-17 07:34:50 -0500"> <meta name="description" content="Deals" /> <meta name="keywords" content="acquisition, asset, purchase, collaboration, development, distributions, equity, option, joint, venture, license, merger, non-profit, research, reverse, royalty, buyout, settlement, spinout, supply, only" /> <link rel="alternate" type="application/xml" title="BioWorld RSS Feed" href="https://www.bioworld.com/rss/articles" /> <meta property="og:title" /> <meta property="og:description" /> <meta property="og:url" /> <meta property="og:type" content="Website" /> <meta content="false" name="has-log-view" /> <title>Deals and M&A - Articles | BioWorld</title> <link rel="stylesheet" media="screen" href="/stylesheets/application.css?v=1739795690" /> <link rel="stylesheet" media="screen" href="/stylesheets/froala.css?v=1739795690" /> <script src="/javascripts/jade.default.min.js?v=1739795690"></script> <script src="/javascripts/application.js?v=1739795690"></script>  <script>var dataLayer = window.dataLayer || [];</script> <script>let snowplowData = {"event":"SnowplowStructuredEvent","product":""}; fetch('/user/snowplow', { method: 'GET', headers: { 'Content-Type': 'application/json' } }) .then(response => { if (!response.ok) { throw new Error(`HTTP error! status: ${response.status}`); } return response.json(); }) .then(data => { const evt = Object.assign({}, snowplowData, data); console.info('Snowplow Data:', evt); // Handle the fetched data dataLayer.push(evt); }) .catch(error => { console.error('Error fetching snowplow data:', error); // Handle any errors });</script><script>dataLayer.push({"id":214,"topics":["Deals and M\u0026A"],"title":"Deals and M\u0026A","page_type":["articles","topic"],"date_posted":"07/19/2019","gated":false,"registered":false});</script> <script>typeof window.dataLayer[0] === 'object' && !('page_type' in window.dataLayer[0]) && window.dataLayer.push({"id":214,"topics":["Deals and M\u0026A"],"title":"Deals and M\u0026A","page_type":["articles","topic"],"date_posted":"07/19/2019","gated":false,"registered":false});</script>   <script> //<![CDATA[ (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5ZV86V9'); //]]> </script>  <script> window.epub = window.epub || {}; window.epub['AD_HISTORY_ENABLED'] = false; </script> <link rel="apple-touch-icon" sizes="180x180" href="/icons/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16x16.png"> <link rel="manifest" href="/icons/site.webmanifest"> <link rel="mask-icon" href="/icons/safari-pinned-tab.svg" color="#5bbad5"> <link rel="shortcut icon" href="/icons/favicon.ico"> <meta name="msapplication-TileColor" content="#00aba9"> <meta name="msapplication-config" content="/icons/browserconfig.xml"> <meta name="theme-color" content="#ffffff"><script> var googletag = { cmd: [] }; var targeting = window.targeting = {"id":"214","tags":["Deals and M\u0026A"],"taxonomy":["Deals and M\u0026A"],"taxonomy_id":[214],"sponsored":"false","page_type":["articles","topic"],"keyword":[],"reg_user":"false","page_name":"214-deals-and-m-a","search_terms":"","url":"/articles/topic/214-deals","site_env":"production"}; </script> <script> (function(ac) { var d = document, s = 'script', id = 'adplugg-adjs'; var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.async = 1; js.src = '//www.adplugg.com/serve/' + ac + '/js/1.1/ad.js'; fjs.parentNode.insertBefore(js, fjs); }('A48225833')); </script><script>if (typeof Oti !== "undefined" && typeof Oti.OtiService !== "undefined") { $.post('/user/pendo', function(data) { const pendoVisitor = data.visitor const pendoAccount = Object.keys(pendoVisitor).length > 0 ? data.account : '' const anomID = localStorage.getItem('anomID') || (localStorage.setItem('anomID', `${navigator.userAgent}-${screen.width}x${screen.height}-${navigator.language}`.split('').reduce((hash, char) => ((hash << 5) - hash) + char.charCodeAt(0), 0).toString(36)) || localStorage.getItem('anomID')) const pendovistorID = (pendoVisitor && Object.keys(pendoVisitor).length > 0 && pendoVisitor.id) ? `${pendoVisitor.id}` : anomID; const otiService = new Oti.OtiService({ ot_key: "603e2c5b-3a1d-4eac-a9c9-fb20c3b528f2", prod_domain: "www.bioworld.com", pendo_key: "34b78be2-b210-4df9-7f2b-7552afe5341c", pendo_details: { visitor: { id: pendovistorID, firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, }, account: { id: pendoAccount } }, pendo_visitor_payload: [{ visitorId: pendovistorID, values: { firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, } }], pendo_visitor_url: '/ui/pendoapi/agent/value?create=true', pendo_dnp_url: `/ui/pendoapi/pendo/value/${pendovistorID}/donotprocess`, pendo_metadata_url: `/ui/pendoapi/custom/value/${pendovistorID}/bioworld_targetingcookies`, }); otiService.initialize(); }); }</script> <link rel="preload" as="script" href="https://cdn.ampproject.org/v0.js"> <script async src="https://cdn.ampproject.org/v0.js"></script>  <style amp-custom>/* Add your styles here */</style> <style amp-boilerplate>body{-webkit-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-moz-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-ms-animation:-amp-start 8s steps(1,end) 0s 1 normal both;animation:-amp-start 8s steps(1,end) 0s 1 normal both}@-webkit-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-moz-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-ms-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-o-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}</style><noscript><style amp-boilerplate>body{-webkit-animation:none;-moz-animation:none;-ms-animation:none;animation:none}</style></noscript> <link rel="canonical" href="."> <script async custom-element="amp-iframe" src="https://cdn.ampproject.org/v0/amp-iframe-0.1.js"></script> <script>var _document$querySelect, _document$querySelect2; var $hasLogViewMeta = (_document$querySelect = document.querySelector('meta[name=has-log-view]')) === null || _document$querySelect === void 0 ? void 0 : _document$querySelect.getAttribute('content'); var $logViewUrlMeta = (_document$querySelect2 = document.querySelector('meta[name=log-view-url]')) === null || _document$querySelect2 === void 0 ? void 0 : _document$querySelect2.getAttribute('content'); if ($hasLogViewMeta === 'true') { var baseLogUrl = (typeof $logViewUrlMeta === "undefined" ? window.location.pathname : $logViewUrlMeta).replace(/(\d+)-.*$/, '$1'); var logUrl = baseLogUrl + '/log_view' + window.location.search; if (typeof navigator.sendBeacon === 'function') { navigator.sendBeacon(logUrl); } else { // Gotta love IE var request = new XMLHttpRequest(); request.open('POST', logUrl, true); request.setRequestHeader('Content-Type', 'application/x-www-form-urlencoded; charset=UTF-8'); request.send(); } }</script> </head> <body data-controller="articles" data-action="topic" data-prestitial-ad="false" data-poststitial-ad="false" data-news-services="">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5ZV86V9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="document mmenu-placeholder"><header class="main-header"><div class="main-header__top"><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a href='https://clarivate.com/cortellis/' target="_blank" class="main-header__logo -clarivate"> <img src="/images/Cortellis_Flagship_Logo.png" alt="Clarivate" title="Powering insights from Cortellis. Link to Cortellis page on Clarivate website."> </a></div><div class="main-nav-container"><div class="main-nav-container__wrapper"><nav id="main-nav" class="main-nav main-nav--horizontal"><div class="navigation"><ul class="main-nav-level1__items"><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/snapshots" href="/snapshots">BioWorld</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/medtech_snapshots" href="/medtech_snapshots">BioWorld MedTech</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li></ul></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Special reports|/special_reports" href="/special_reports">Special reports</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Trump administration impacts|/Trump_administration_impacts" href="/Trump_administration_impacts">Trump administration impacts</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biopharma M&A scorecard|/biopharma_MandA_scorecard" href="/biopharma_MandA_scorecard">Biopharma M&A scorecard</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld 2024 review|/BioWorld_2024_review" href="/BioWorld_2024_review">BioWorld 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech 2024 review|https://www.bioworld.com/medtech_trends_2024" href="https://www.bioworld.com/medtech_trends_2024">BioWorld MedTech 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science 2024 review|/BioWorld_Science_2024_review" href="/BioWorld_Science_2024_review">BioWorld Science 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Women's health|/womens_health" href="/womens_health">Women's health</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China's GLP-1 landscape|/China_GLP-1" href="/China_GLP-1">China's GLP-1 landscape</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="PFA re-energizes afib market|https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market" href="https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market">PFA re-energizes afib market</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China CAR T|/China_CAR_T" href="/China_CAR_T">China CAR T</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Alzheimer's disease|/Alzheimers" href="/Alzheimers">Alzheimer's disease</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Israel|/israel" href="/israel">Israel</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Rise of obesity|/rise_of_obesity" href="/rise_of_obesity">Rise of obesity</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Radiopharmaceuticals|/radiopharmaceuticals" href="/radiopharmaceuticals">Radiopharmaceuticals</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biosimilars|/biosimilars" href="/biosimilars">Biosimilars</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Aging|/aging" href="/aging">Aging</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="IVDs on the rise|/IVDs-2021" href="/IVDs-2021">IVDs on the rise</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Coronavirus|/articles/topic/517" href="/articles/topic/517">Coronavirus</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Artificial intelligence|/AI_series" href="/AI_series">Artificial intelligence</a></li></ul></li></ul></div></nav><div class="main-nav-container__mobile-nav"><a class="hamburger-nav-link" href="#" id="hamburger-nav-link"></a><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a class="search-nav-link" href="#" id="search-nav-link"></a><form action="/search" class="mobile-search" id="mobile-search" method="get"><input class="mobile-search__field" name="q" placeholder="What are you looking for?" type="text" /><button class="mobile-search__icon" type="submit"></button></form></div><div class="main-nav-container__nav2"><nav class="user-actions" id="user-actions"> <ul class="user-actions__list"> <li class="user-actions__signin"> <a class="user-actions__signin-link" href="/user/login">Sign In</a> </li> <li class="user-actions__signout"> <a class="user-actions__signout-link" href="/user/logout">Sign Out</a> </li> <li class="user-actions__account"> <a class="user-actions__account-link" href="/user/profile">My Account</a> </li> </ul> </nav> <a class="main-nav-container__subscribe-link" href="/subscriptions">Subscribe</a><div class="quick-search" id="quick-search"><form action="/search" id="quick-search-form" method="GET" name="quick-search" target="_top"><div class="quick-search__wrapper" role="presentation"><input class="quick-search__search-field" id="q" name="q" placeholder="Search" type="text" /><button class="quick-search__button" title="Search" type="submit"></button></div></form></div></div></div></div></header><div class="container"><section class="site-banner" id="site-banner"><div class="site-banner__date">BioWorld - Monday, February 17, 2025</div></section><div id="section-2" class="main-body"> <script src="/javascripts/pages/article.js?v=1739795690"></script> <div id="breadcrumbs" class="breadcrumbs"><a class="" href="/">Home</a> » <a class="" href="/topics">Topics</a> » Deals and M&A</div> <div class="box1 article-topic"> <div class="records"> <h1 class="page-title"> Deals and M&A <div class="rss"> <a href="/rss/topic/214-deals-and-m-a"> <img alt="Deals and M&A RSS Feed" height="16" width="16" loading="lazy" src="/images/icons/rss.gif" /> RSS </a> </div> </h1> <article class="record article-summary "> <div class="article-summary__details "> <div class="kicker article-summary__kicker">Biopharma deals January 2025</div> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717342-biopharma-kicks-off-strong-in-2025-with-286b-in-january-deals">Biopharma kicks off strong in 2025, with $28.6B in January deals </a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 14, 2025</div> <div class="author article-summary__author">By <a href="/authors/18-amanda-lanier">Amanda Lanier</a></div> <div class="comment-count article-summary__comment-count"><a title="Biopharma kicks off strong in 2025, with $28.6B in January deals " class="more" href="https://www.bioworld.com/articles/717342-biopharma-kicks-off-strong-in-2025-with-286b-in-january-deals#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Biopharma deal activity in the first month of the year saw the largest January raise thus far, with $28.63 billion in collective funds. While down slightly month over month, the value was comparable to December 2024’s $29.02 billion and November 2024’s $29.34 billion.<br /></div><a title="Biopharma kicks off strong in 2025, with $28.6B in January deals " class="more" href="https://www.bioworld.com/articles/717342-biopharma-kicks-off-strong-in-2025-with-286b-in-january-deals">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Ligachem gets rights to Daan’s antibody for solid tumor ADCs" class="url" rel="" target="" href="https://www.bioworld.com/articles/717260-ligachem-gets-rights-to-daans-antibody-for-solid-tumor-adcs"><img width="650" height="488" alt="Antibody-drug conjugate" title="Antibody-drug conjugate" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Antibody-drug-conjugate.png?height=488&t=1632175105&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717260-ligachem-gets-rights-to-daans-antibody-for-solid-tumor-adcs">Ligachem gets rights to Daan’s antibody for solid tumor ADCs</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 13, 2025</div> <div class="author article-summary__author">By <a href="/authors/603-marian-yoonjee-chu">Marian (YoonJee) Chu</a></div> <div class="comment-count article-summary__comment-count"><a title="Ligachem gets rights to Daan’s antibody for solid tumor ADCs" class="more" href="https://www.bioworld.com/articles/717260-ligachem-gets-rights-to-daans-antibody-for-solid-tumor-adcs#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs), this time with T-cell receptor therapy specialist Daan Biotherapeutics Inc. for a cancer-targeting antibody.<br /></div><a title="Ligachem gets rights to Daan’s antibody for solid tumor ADCs" class="more" href="https://www.bioworld.com/articles/717260-ligachem-gets-rights-to-daans-antibody-for-solid-tumor-adcs">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses" class="url" rel="" target="" href="https://www.bioworld.com/articles/717211-apac-deals-abound-lilly-taps-advancell-olix-genome-draws-ellipses"><img width="650" height="488" alt="Business people with hands atop a digital globe" title="Business people with hands atop a digital globe" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-deal-merger.png?height=488&t=1588280366&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717211-apac-deals-abound-lilly-taps-advancell-olix-genome-draws-ellipses">APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 12, 2025</div> <div class="author article-summary__author">By <a href="/authors/603-marian-yoonjee-chu">Marian (YoonJee) Chu</a></div> <div class="comment-count article-summary__comment-count"><a title="APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses" class="more" href="https://www.bioworld.com/articles/717211-apac-deals-abound-lilly-taps-advancell-olix-genome-draws-ellipses#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, under undisclosed terms Feb. 11.<br /></div><a title="APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses" class="more" href="https://www.bioworld.com/articles/717211-apac-deals-abound-lilly-taps-advancell-olix-genome-draws-ellipses">Read More</a> </div> </article> <article class="record article-summary "> <div class="article-summary__details "> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717208-abbvie-engaged-again-vows-21b-pus-in-xilio-t-cell-pact">Abbvie engaged again, vows $2.1B-plus in Xilio T cell pact</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 12, 2025</div> <div class="author article-summary__author">By <a href="/authors/17-randy-osborne">Randy Osborne</a></div> <div class="comment-count article-summary__comment-count"><a title="Abbvie engaged again, vows $2.1B-plus in Xilio T cell pact" class="more" href="https://www.bioworld.com/articles/717208-abbvie-engaged-again-vows-21b-pus-in-xilio-t-cell-pact#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Xilio Therapeutics Inc. is banking $52 million up front from Abbvie Inc., including a $10 million equity investment, plus about $2.1 billion in contingent payments for option-related fees and milestones, plus tiered royalties, as the pair embarks on developing tumor-activated, antibody-based immunotherapies, including masked T-cell engagers.<br /></div><a title="Abbvie engaged again, vows $2.1B-plus in Xilio T cell pact" class="more" href="https://www.bioworld.com/articles/717208-abbvie-engaged-again-vows-21b-pus-in-xilio-t-cell-pact">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Olix wins $630M deal from Eli Lilly for phase I MASH asset" class="url" rel="" target="" href="https://www.bioworld.com/articles/717278-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset"><img width="650" height="488" alt="Liver illustration" title="Liver illustration " border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration-purple.jpg?height=488&t=1705415419&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717278-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset">Olix wins $630M deal from Eli Lilly for phase I MASH asset</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 11, 2025</div> <div class="author article-summary__author">By <a href="/authors/603-marian-yoonjee-chu">Marian (YoonJee) Chu</a></div> <div class="comment-count article-summary__comment-count"><a title="Olix wins $630M deal from Eli Lilly for phase I MASH asset" class="more" href="https://www.bioworld.com/articles/717278-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.<br /></div><a title="Olix wins $630M deal from Eli Lilly for phase I MASH asset" class="more" href="https://www.bioworld.com/articles/717278-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Chinese biotechs aim to clear high hurdles with overseas spinouts" class="url" rel="" target="" href="https://www.bioworld.com/articles/717277-chinese-biotechs-aim-to-clear-high-hurdles-with-overseas-spinouts"><img width="650" height="488" alt="China in red on globe" title="China in red on globe" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-globe.png?height=488&t=1651790131&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717277-chinese-biotechs-aim-to-clear-high-hurdles-with-overseas-spinouts">Chinese biotechs aim to clear high hurdles with overseas spinouts</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 11, 2025</div> <div class="author article-summary__author">By <a href="/authors/49-tamra-sami">Tamra Sami</a></div> <div class="comment-count article-summary__comment-count"><a title="Chinese biotechs aim to clear high hurdles with overseas spinouts" class="more" href="https://www.bioworld.com/articles/717277-chinese-biotechs-aim-to-clear-high-hurdles-with-overseas-spinouts#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Chinese biotechs are increasingly seeking deals with multinational companies, and those deal structures are getting more creative. The “newco” deal structure is getting a lot of attention, but the barrier for entry is quite high for this type of deal, Morrison Foerster Shanghai Managing Partner Chuan Sun told <em>BioWorld</em>.<br /></div><a title="Chinese biotechs aim to clear high hurdles with overseas spinouts" class="more" href="https://www.bioworld.com/articles/717277-chinese-biotechs-aim-to-clear-high-hurdles-with-overseas-spinouts">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Novartis paying up to $3.1B for cardio specialist Anthos" class="url" rel="" target="" href="https://www.bioworld.com/articles/717104-novartis-paying-up-to-31b-for-cardio-specialist-anthos"><img width="650" height="488" alt="AI-generated illustration of heart and metabolic impact" title="AI-generated illustration of heart and metabolic impact" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Cardiometabolic-illustration.jpg?height=488&t=1718750919&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717104-novartis-paying-up-to-31b-for-cardio-specialist-anthos">Novartis paying up to $3.1B for cardio specialist Anthos</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 11, 2025</div> <div class="author article-summary__author">By <a href="/authors/64-lee-landenberger">Lee Landenberger</a></div> <div class="comment-count article-summary__comment-count"><a title="Novartis paying up to $3.1B for cardio specialist Anthos" class="more" href="https://www.bioworld.com/articles/717104-novartis-paying-up-to-31b-for-cardio-specialist-anthos#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Novartis AG is paying nearly $1 billion up front to buy privately held Anthos Therapeutics Inc. in a deal that eventually could top out around $3.1 billion. Novartis, coming back to where it started as it and Blackstone Life Sciences founded Anthos in 2019, is entering a crowded space.<br /></div><a title="Novartis paying up to $3.1B for cardio specialist Anthos" class="more" href="https://www.bioworld.com/articles/717104-novartis-paying-up-to-31b-for-cardio-specialist-anthos">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Ellipses Pharma licenses monoclonal antibody targeting CNTN4 from Genome & Co." class="url" rel="" target="" href="https://www.bioworld.com/articles/717186-ellipses-pharma-licenses-monoclonal-antibody-targeting-cntn4-from-genome-and-co"><img width="650" height="488" alt="Illustration of T cells attacking tumor" title="Illustration of T cells attacking tumor" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/tcells-attacking-tumor.jpg?height=488&t=1734452639&width=650" /></a></div> <div class="article-summary__details has-image"> <div class="kicker article-summary__kicker">Immuno-oncology</div> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717186-ellipses-pharma-licenses-monoclonal-antibody-targeting-cntn4-from-genome-and-co">Ellipses Pharma licenses monoclonal antibody targeting CNTN4 from Genome & Co.</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 11, 2025</div> <div class="comment-count article-summary__comment-count"><a title="Ellipses Pharma licenses monoclonal antibody targeting CNTN4 from Genome & Co." class="more" href="https://www.bioworld.com/articles/717186-ellipses-pharma-licenses-monoclonal-antibody-targeting-cntn4-from-genome-and-co#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, from Genome & Co. Ltd. Targeting CNTN4 is a new approach that blocks the CNTN4-APP checkpoint interaction on T cells, promoting tumor cell killing, with potential use in cancers that respond poorly to conventional checkpoint inhibitors.<br /></div><a title="Ellipses Pharma licenses monoclonal antibody targeting CNTN4 from Genome & Co." class="more" href="https://www.bioworld.com/articles/717186-ellipses-pharma-licenses-monoclonal-antibody-targeting-cntn4-from-genome-and-co">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Olix wins $630M deal from Eli Lilly for phase I MASH asset" class="url" rel="" target="" href="https://www.bioworld.com/articles/717092-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset"><img width="650" height="488" alt="Liver illustration" title="Liver illustration " border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration-purple.jpg?height=488&t=1705415419&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717092-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset">Olix wins $630M deal from Eli Lilly for phase I MASH asset</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 10, 2025</div> <div class="author article-summary__author">By <a href="/authors/603-marian-yoonjee-chu">Marian (YoonJee) Chu</a></div> <div class="comment-count article-summary__comment-count"><a title="Olix wins $630M deal from Eli Lilly for phase I MASH asset" class="more" href="https://www.bioworld.com/articles/717092-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock by 30% after it had largely recovered from a terminated deal with France’s Théa Open Innovation last year.<br /></div><a title="Olix wins $630M deal from Eli Lilly for phase I MASH asset" class="more" href="https://www.bioworld.com/articles/717092-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea" class="url" rel="" target="" href="https://www.bioworld.com/articles/717075-tyk2s-to-tango-ted-dead-alumis-acelyrin-merger-a-capital-idea"><img width="650" height="488" alt="M&A letters over missing puzzle pieces" title="M&A letters over missing puzzle pieces" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/MA-missing-puzzle-pieces.jpg?height=488&t=1714688552&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717075-tyk2s-to-tango-ted-dead-alumis-acelyrin-merger-a-capital-idea">TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 7, 2025</div> <div class="author article-summary__author">By <a href="/authors/17-randy-osborne">Randy Osborne</a></div> <div class="comment-count article-summary__comment-count"><a title="TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea" class="more" href="https://www.bioworld.com/articles/717075-tyk2s-to-tango-ted-dead-alumis-acelyrin-merger-a-capital-idea#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">In a deal that Cantor Fitzgerald analyst Eric Schmidt characterized as “capital recycling at its best,” Alumis Inc. and Acelyrin Inc. are merging in an all-stock transaction. The combined pipelines include Alumis’ most advanced prospect, ESK-001, an oral, next-generation, allosteric inhibitor of tyrosine kinase 2 (TYK2). ESK-001 is undergoing the phase III Onward study for moderate to severe plaque psoriasis as well as the phase II Lumus bid in systemic lupus erythematosus.<br /></div><a title="TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea" class="more" href="https://www.bioworld.com/articles/717075-tyk2s-to-tango-ted-dead-alumis-acelyrin-merger-a-capital-idea">Read More</a> </div> </article> </div> <div class="pager"> <div role="navigation" aria-label="Pagination" class="pagination"><span class="previous_page disabled" aria-disabled="true">Previous</span> <em class="current" aria-label="Page 1" aria-current="page">1</em> <a rel="next" aria-label="Page 2" href="/articles/topic/214-deals-bioworld-asia?page=2">2</a> <a aria-label="Page 3" href="/articles/topic/214-deals-bioworld-asia?page=3">3</a> <a aria-label="Page 4" href="/articles/topic/214-deals-bioworld-asia?page=4">4</a> <a aria-label="Page 5" href="/articles/topic/214-deals-bioworld-asia?page=5">5</a> <a aria-label="Page 6" href="/articles/topic/214-deals-bioworld-asia?page=6">6</a> <a aria-label="Page 7" href="/articles/topic/214-deals-bioworld-asia?page=7">7</a> <a aria-label="Page 8" href="/articles/topic/214-deals-bioworld-asia?page=8">8</a> <a aria-label="Page 9" href="/articles/topic/214-deals-bioworld-asia?page=9">9</a> <span class="gap">…</span> <a aria-label="Page 261" href="/articles/topic/214-deals-bioworld-asia?page=261">261</a> <a aria-label="Page 262" href="/articles/topic/214-deals-bioworld-asia?page=262">262</a> <a class="next_page" rel="next" href="/articles/topic/214-deals-bioworld-asia?page=2">Next</a></div> </div> </div> </div><aside class="main-interior-sidebar"><div class="main-interior-sidebar__column"><div id="article-recommendations"></div> </div><div class="main-interior-sidebar__column"><section class="popular-stories "> <h1 class="popular-stories__title">Popular Stories</h1><ul class="popular-stories__items"> <li class="popular-stories__item"> <article class="popular-stories__article popular-stories--article"><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/432891-todays-news-in-brief">Today's news in brief</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/84-bioworld">BioWorld</a></div><div class="popular-stories__teaser"><em>BioWorld</em> briefs for Feb. 14, 2025.</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/716835-european-vcs-optimistic-for-med-tech-exit-opportunities-in-2025" href="https://www.bioworld.com/articles/716835-european-vcs-optimistic-for-med-tech-exit-opportunities-in-2025"><img class="popular-stories__image-thumb" alt="Gold Euro symbol on blue background" title="Gold Euro symbol on blue background" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.jpg?height=355&t=1729028866&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/716835-european-vcs-optimistic-for-med-tech-exit-opportunities-in-2025">European VCs optimistic for med-tech exit opportunities in 2025</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser">To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article popular-stories--article"><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/699574-todays-news-in-brief">Today's news in brief</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser"><em>BioWorld MedTech</em> briefs for February 14, 2025</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025" href="https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025"><img class="popular-stories__image-thumb" alt="White Euro symbol on blue background" title="White Euro symbol on blue background" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Money/Euro-currency-symbol-white.png?height=355&t=1669153720&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025">European VCs bullish on med-tech investments in 2025</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser">European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/717003-kura-kyowa-kirins-ziftomenib-hits-phase-ii-endpoints-in-aml" href="https://www.bioworld.com/articles/717003-kura-kyowa-kirins-ziftomenib-hits-phase-ii-endpoints-in-aml"><img class="popular-stories__image-thumb" alt="3D illustration of acute myeloid leukemia cells" title="3D illustration of acute myeloid leukemia cells" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/AML-Acute-Myekoid-Leukemia-Cells.jpg?height=355&t=1718812728&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/717003-kura-kyowa-kirins-ziftomenib-hits-phase-ii-endpoints-in-aml">Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/84-bioworld">BioWorld</a></div><div class="popular-stories__teaser">Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...</div></div></article> </li> </ul> </section></div><div class="main-interior-sidebar__column"><div class="adplugg-tag" data-adplugg-zone="promo_1"></div></div></aside></div><footer class="main-footer"><div class="main-footer__top"><nav id="footer-1" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Today's news|/topics/84-bioworld" href="/topics/84-bioworld">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Analysis and data insight|/articles/topic/84,109-analysis-and-data-insight-bioworld" href="/articles/topic/84,109-analysis-and-data-insight-bioworld">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Clinical|/articles/topic/84,153-clinical-bioworld" href="/articles/topic/84,153-clinical-bioworld">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Deals and M&A|/articles/topic/84,214-deals-bioworld" href="/articles/topic/84,214-deals-bioworld">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Financings|/articles/topic/84,292-financings-bioworld" href="/articles/topic/84,292-financings-bioworld">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Newco news|/articles/topic/84,391-newco-news-bioworld" href="/articles/topic/84,391-newco-news-bioworld">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Opinion|/blogs/1-bioworld-perspectives" href="/blogs/1-bioworld-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Regulatory|/articles/topic/84,402-regulatory-bioworld" href="/articles/topic/84,402-regulatory-bioworld">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Science|/articles/topic/84,110-science-bioworld" href="/articles/topic/84,110-science-bioworld">Science</a></li></ul></li></ul></div></nav><nav id="footer-2" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Today's news|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Clinical|/articles/topic/85,153-clinical-bioworld-medtech" href="/articles/topic/85,153-clinical-bioworld-medtech">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Data Snapshots|/medtech_snapshots" href="/medtech_snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Deals and M&A|/articles/topic/85,214-deals-bioworld-medtech" href="/articles/topic/85,214-deals-bioworld-medtech">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Financings|/articles/topic/85,292-financings-bioworld-medtech" href="/articles/topic/85,292-financings-bioworld-medtech">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Newco news|/articles/topic/85,391-newco-news-bioworld-medtech" href="/articles/topic/85,391-newco-news-bioworld-medtech">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Opinion|/blogs/2-bioworld-medtech-perspectives" href="/blogs/2-bioworld-medtech-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Regulatory|/articles/topic/85,402-regulatory-bioworld-medtech" href="/articles/topic/85,402-regulatory-bioworld-medtech">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Science|/articles/topic/85,110-science-bioworld-medtech" href="/articles/topic/85,110-science-bioworld-medtech">Science</a></li></ul></li></ul></div></nav><nav id="footer-3" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Today's news|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Analysis and data insight|/articles/topic/86,109-analysis-and-data-insight-bioworld-asia" href="/articles/topic/86,109-analysis-and-data-insight-bioworld-asia">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Australia|/articles/topic/86,394-australia-bioworld-asia" href="/articles/topic/86,394-australia-bioworld-asia">Australia</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="China|/articles/topic/86,395-china-bioworld-asia" href="/articles/topic/86,395-china-bioworld-asia">China</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Clinical|/articles/topic/86,153-clinical-bioworld-asia" href="/articles/topic/86,153-clinical-bioworld-asia">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Deals and M&A|/articles/topic/86,214-deals-bioworld-asia" href="/articles/topic/86,214-deals-bioworld-asia">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Financings|/articles/topic/86,292-financings-bioworld-asia" href="/articles/topic/86,292-financings-bioworld-asia">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Newco news|/articles/topic/86,391-newco-news-bioworld-asia" href="/articles/topic/86,391-newco-news-bioworld-asia">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Regulatory|/articles/topic/86,402-regulatory-bioworld-asia" href="/articles/topic/86,402-regulatory-bioworld-asia">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Science|/articles/topic/86,110-science-bioworld-asia" href="/articles/topic/86,110-science-bioworld-asia">Science</a></li></ul></li></ul></div></nav><nav id="footer-5" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Today's news|/topics/520-bioworld-science" href="/topics/520-bioworld-science">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Biomarkers|/articles/topic/520,543-biomarkers-bioworld-science" href="/articles/topic/520,543-biomarkers-bioworld-science">Biomarkers</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Cancer|/articles/topic/520,239-cancer-bioworld-science" href="/articles/topic/520,239-cancer-bioworld-science">Cancer</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Conferences|/articles/topic/520,154-conferences-bioworld-science" href="/articles/topic/520,154-conferences-bioworld-science">Conferences</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Endocrine/Metabolic|/articles/topic/520,246-endocrine-metabolic-bioworld-science" href="/articles/topic/520,246-endocrine-metabolic-bioworld-science">Endocrine/Metabolic</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Immune|/articles/topic/520,250-immune-bioworld-science" href="/articles/topic/520,250-immune-bioworld-science">Immune</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Infection|/articles/topic/520,251-infection-bioworld-science" href="/articles/topic/520,251-infection-bioworld-science">Infection</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Neurology/Psychiatric|/articles/topic/520,256-neurology-psychiatric-bioworld-science" href="/articles/topic/520,256-neurology-psychiatric-bioworld-science">Neurology/Psychiatric</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Patents|/articles/topic/520,472-patents-bioworld-science" href="/articles/topic/520,472-patents-bioworld-science">Patents</a></li></ul></li></ul></div></nav><nav id="footer-4" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="More|javascript:void(0);" href="javascript:void(0);">More</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="About|/about" href="/about">About</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Advertise with BioWorld|/advertising" href="/advertising">Advertise with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Archives|/newsletters" href="/newsletters">Archives</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Article reprints and permissions|/reprints" href="/reprints">Article reprints and permissions</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Contact us|https://clarivate.com/cortellis/contact-us/" target="_blank" href="https://clarivate.com/cortellis/contact-us/">Contact us</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Cookie policy|https://clarivate.com/legal/cookie-policy/" target="_blank" href="https://clarivate.com/legal/cookie-policy/">Cookie policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Copyright notice|https://clarivate.com/legal/copyright-notice/" target="_blank" href="https://clarivate.com/legal/copyright-notice/">Copyright notice</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Data methodology|/content/methodology-chart" href="/content/methodology-chart">Data methodology</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Podcasts|/media/podcasts/532-bioworld-insider-podcast" href="/media/podcasts/532-bioworld-insider-podcast">Podcasts</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Privacy policy|https://clarivate.com/legal/privacy-policy/" target="_blank" href="https://clarivate.com/legal/privacy-policy/">Privacy policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Share your news with BioWorld|/share_your_news" href="/share_your_news">Share your news with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Staff|/staff" href="/staff">Staff</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Terms of use|https://clarivate.com/legal/terms-of-use/" target="_blank" href="https://clarivate.com/legal/terms-of-use/">Terms of use</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Topic alerts|/rss" href="/rss">Topic alerts</a></li></ul></li></ul></div></nav></div><div class="main-footer__bottom"><a class="social-media-links" title="Follow us" href="/social-media"><div class="social-media-links__callout">Follow Us</div><div class="social-media-links__twitter"></div> <div class="social-media-links__linkedin"></div></a></div><p class="main-footer__copyright">Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: <a href="http://www.epublishing.com" target="_blank">ePublishing</a><br /><button class="ot-sdk-show-settings" id="ot-sdk-btn" style="margin-top: 1rem">Cookie Settings</button></p></footer></div> <script async="async"> //<![CDATA[ require(['bundle/main.bundle']); //]]> </script> </body></html>